Amanda Carbonell

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 6 papers. Top paper: “Selumetinib in Children with Inoperable Plexiform Neurofibromas”.

Selumetinib in Children with Inoperable Plexiform Neurofibromas

New England Journal of Medicine(2020)10.1056/nejmoa1912735

N/A

9.0DataRank · unranked

708 citations

Pamela L. Wolters, Eva Dombi, Andrea Baldwin, Patricia Whitcomb, Michael J. Fisher +24 more

Immune determinants of CAR-T cell expansion in solid tumor patients receiving GD2 CAR-T cell therapy

Cancer Cell(2023)10.1016/j.ccell.2023.11.011

N/A

2.4DataRank · unranked

110 citations

Tara Murty, Ahmad Alimadadi, Cristina F. Contreras, Caroline Duault, Priyanka B. Subrahmanyam +39 more

Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity

Neuro-Oncology(2022)10.1093/neuonc/noac109

N/A

1.7DataRank · unranked

66 citations

Brittany Glassberg, Pamela L. Wolters, Eva Dombi, Andrea Baldwin, Michael J. Fisher +18 more

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2168

N/A

0.815DataRank · unranked

22 citations

R. Taylor Sundby, Mary Frances Wedekind, Fernanda I. Arnaldez, Jaydira Del Rivero, Lori Wiener +27 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0.483DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa095

N/A

0DataRank · unranked

38 citations

Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin, Joanne Derdak +9 more